Merck Annual Report 2011 - Sitemap (optimized for printing)

Merck 2011 at a glance
- Letter from Karl-Ludwig Kley
- Executive Board
- Key Events in 2011
- Business Development 2002-2011
- Financial Calendar
Corporate Governance
- Statement on Corporate Governance
  - Merck KGaA
  - Compensation report
    - Executive Board
    - Supervisory Board
    - Ownership of shares
- Corporate Governance Practices
  - Principles
  - Values and compliance
- Procedures of the corporate bodies
  - Executive Board
  - Supervisory Board
  - Board of Partners of E. Merck KG
- Report of the Supervisory Board
- Objectives of the Supervisory Board
Merck in the Capital Market
- Share price development
- Share data
- Shareholder
- Merck bonds
Group Management Report
- Economic Situation
- Financial Position and Results of Operations
  - Business development
  - Business sectors
  - Regions
  - Acquisitions
  - Total assets
  - Free cash flow
  - Capital spending
  - Key financial performance indicators
  - Value added
  - Capital and shares
- Corporate Responsibility
  - Employees
  - International human resources work
  - Diversity in the workforce
  - Products and the environment
  - Society
- Corporate and Other
- Risk Report
  - Business-related risks
  - Financial risks
  - Legal risks
  - Human resources risks
  - Information technology risks
  - Environmental and safety risks
- Report on Expected Developments
  - Global economy
  - Forecast for sales and operating result
- Subsequent Events
Merck Serono
- Business development
- Regions
- Therapeutic areas
  - Oncology
  - Multiple Sclerosis
  - Fertility
  - Endocrinology
  - CardioMetabolic Care and General Medicine
- Research & Development
  - Overview compounds
  - Oncology
  - Multiple sclerosis
  - Parkinson
  - Fertility
  - Endocrinology
  - Rheumatological diseases
Consumer Health Care
- Business development
- Brands
- Regions
Merck Millipore
- Business development
- BioScience
- Lab Solutions
- Process Solutions
Performance Materials
- Business development
- Liquid Crystals
- Pigments & Cosmetics
Financial Statements
- Income Statement
- Comprehensive Income
- Balance Sheet
- Cash Flow Statement
- Changes in Net Equity
Notes
- Scope of consolidation
- Accounting policies
- Notes to the consolidated income statement
  - Sales
  - Royalty, license and commission income
  - Cost of sales
  - Marketing and selling expenses
  - Royalty, license and commission expenses
  - Administration expenses
  - Other operating expenses and income
  - Research and development
  - Amortization of intangible assets
  - Investment result
  - Exceptional items
  - Financial result
  - Income tax
  - Non-controlling interest
  - Earnings per share
- Notes to the consolidated balance sheet
  - Cash and cash equivalents
  - Marketable securities and financial assets
  - Trade accounts receivable
  - Inventories
  - Other assets
  - Tax receivables
  - Assets held for sale and liabilities directly related to assets held for sale
  - Intangible assets
  - Property, plant and equipment
  - Investments at equity
  - Non-current financial assets
  - Financial assets covering pension obligations
  - Financial liabilities
  - Trade accounts payable
  - Other liabilities
  - Tax liabilities
  - Provisions
  - Provisions for pensions and other post-employment benefits
  - Equity
- Segment reporting
- Notes to the consolidated cash flow statement
  - Net cash flows from operating activities
  - Net cash flows from investing activities
  - Net cash flows from financing activities
  - Cash and cash equivalents
  - Free cash flow and underlying free cash flow
- Other disclosures
  - Derivative financial instruments
  - Management of financial risks
  - Other disclosures on financial instruments
  - Capital management
  - Contingent liabilities
  - Other financial obligations
  - Personnel expenses / Headcount
  - Material costs
  - Auditors’ fees
  - Corporate governance
  - Companies opting for exemption under section 264 (3) HGB
  - Related-party disclosures
  - Executive Board and Supervisory Board compensation
  - Information on preparation and approval
  - Subsequent events
  - List of shareholdings
- Auditor’s Report
The road to tomorrow
- Innovative
- Dynamic
- Future-oriented
- Values-based
- Merck: Fit for 2018